Skip to main content


Figure 3 | BMC Cancer

Figure 3

From: Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer

Figure 3

Analysis of pSrc and pFAK expression in sequential liver metastases resected from the same patients. Patients were treated with no chemotherapy before the first resection and either with an oxaliplatin-based regimen, an irinotecan-based regimen, or no chemotherapy between resections (cohort 2, N = 15 for pSrc and N = 16 for pFAK). Each pair of points represents a single patient. Patients exposed to oxaliplatin demonstrated an increased in activated pFAK and a trend towards increased pSrc that was not observed in the patients who received no chemotherapy or an irinotecan-based regimen.

Back to article page